April 14, 2021
PharmaCCX is pleased to announce that Dr. Brian O'Rourke has agreed to join the company's advisory board where he will advise the company on strategy based on his extensive experience and work in health technology assessment.
Brian O'Rourke has joined PharmaCCX, a price negotiation and tracking platform for payers and pharma, as a member of the company's Advisory Board.
Prior to this role with PharmaCCX, Brian was President and CEO of CADTH (Canadian Agency for Drugs and Technologies in Health) for 11 years. He joined CADTH following a distinguished career as a Pharmacist and Health Care Executive with the Canadian military.
With over 40 years of experience in health care, Brian is a leading expert in the science and practice of health technology assessment (HTA) and served as the Board Chair for the International Network of Agencies for Health Technology Assessment from 2014 to 2018. Dr. O’Rourke continues to play an active role in the global HTA community. He is the Chair of the Health Technology Assessment Steering Committee and a member of the Scientific Advisory Council for the Centre for Innovation in Regulatory Science (CIRS). He is also Chair of the Health Technology Assessment Council of the Professional Society for Health Economics and Outcomes Research (ISPOR).
"Brian brings a profound perspective that will help us build a better product that addresses our pharma and payer partners needs. His broad experience will help us deploy it in a way that fits the needs of a very diverse set of users and use cases. We're excited to have him as part of our work" said Nathan Sigworth, CEO of PharmaCCX.
“CCX is building the 'stock exchange for therapies' that will make innovative deal making and deal management faster and easier to scale" said Brian O'Rourke. “I'm glad to help guide the team and help shape a tool that can help in very practical ways. By using the PharmaCCX platform, colleagues from pharma and the payer community will get innovative therapies to patients faster and more efficiently.”
Brian brings profound perspective that will help us build a better product that addresses our pharma and payer partners needs.